---
run_id: halo-evidence-vs-diagnosis-validation-v7-vanilla-06
created: 2026-05-23
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
model_condition: vanilla
run_number: 6
model_name: gemma4:31b
model_id: gemma4:31b
model_snapshot: Ollama model ID 6316f0629137
runtime: Ollama local HTTP server; version 0.24.0
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
seed: 601
prompt_source: condition packet (vanilla) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
source_packet: the frozen Advisor prompt alone, with no added material - see run-packet.md
source_packet_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
condition_packet_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
output_file: model-outputs/vanilla-06.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - vanilla (run 06)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v7-v1`, condition `vanilla`, run 6 of 8. Real local-model run: `gemma4:31b` via Ollama, seed 601, on the frozen condition packet.

## Output

I recommend you advise the CEO to commit to the **Targeted Evidence Pass**.

### The Reasoning
Your company is currently experiencing a "false positive" growth cycle. The upbeat board narrative is built on lagging indicators (revenue) that have been artificially inflated by sales incentives (six-month discounts) and biased feedback (quotes collected after telling customers the feature is the top priority).

The leading indicators—the only ones that matter for long-term retention—are flashing red:
1. **The Value Gap:** A 31% return rate for front-line reviewers indicates a failure of the core value proposition. The tool is not solving the reviewer's problem; it is creating a new one (explaining the AI to auditors).
2. **The Usage Mirage:** The 44% usage spike is driven by "power users" (ops champions) using the tool for administrative prep, not by the actual workforce performing the triage.
3. **The Hidden Churn:** The non-renewal letters are the "canary in the coal mine." The revenue bump is a temporary sugar high that will crash the moment the discounts expire and procurement windows open.

Scaling now (Option 1) would be committing the budget to a product that lacks Product-Market Fit, essentially funding a massive churn event in 12 months. Narrowing the focus immediately (Option 3) is a premature pivot based on a single segment's failure without knowing if the tool is actually viable for the other segments. You must strip away the sales noise to see if there is a real product signal.

### The Strongest Reason Against This
**It kills the current momentum and risks a "narrative collapse" with the board.**
The CEO is currently riding a wave of positive sentiment. Recommending a "pause" on discounts and a period of instrumentation will likely result in a dip in short-term NRR and a cooling of the "customer-obsessed" narrative. To the CEO and Sales leadership, this will look like Product is acting as a brake on a winning streak, potentially making you appear overly cautious or "academic" while the competition is moving faster.

### Evidence That Would Change My Mind
I would pivot to the **Broad Scale (Option 1)** if you can provide evidence that the **Compliance Operations Champions** (the ones rerunning queues) are the primary economic buyers and that their specific use case—oversight and enablement—is a high-value pain point they are willing to pay for *without* the discount.

If the "champion" is the one signing the check and they value the "sample queue" functionality more than the "front-line triage" functionality, then the 31% reviewer retention is irrelevant. In that specific scenario, the product isn't a "triage tool"; it's a "management oversight tool," and scaling it as such would be the correct move.
